No abstract

The orexin/hypocretin receptors are a family of G protein-coupled receptors and consist of orexin-1 (OX1) and orexin-2 (OX2) receptor subtypes. Orexin receptors are expressed throughout the central nervous system and are involved in the regulation of the sleep/wake cycle. Because modulation of these receptors constitutes a promising target for novel treatments of disorders associated with the control of sleep and wakefulness, such as insomnia, the development of orexin receptor antagonists has emerged as an important focus in drug discovery research. Here, we report the design, synthesis, characterization, and structure-activity relationships (SARs) of novel orexin receptor antagonists. Various modifications made to the core structure of a previously developed compound (-)-5, the lead molecule, resulted in compounds with improved chemical and pharmacological profiles. The investigation afforded a potential therapeutic agent, (1R,2S)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006), an orally active, potent orexin antagonist. The efficacy was demonstrated in mice in an in vivo study by using sleep parameter measurements.

No abstract

By injection of microwave power P EC near the electron cyclotron (EC) frequency into an Ohmically heated (OH) plasma in the WT-2 tokamak after OH power is shut off, the plasma current is sustained and ramped up by the EC wave only, without OH power. Here, EC-driven current is generated by EC heating of the suprathermal electron beam in OH plasma. Further, when P EC is injected into plasma sustained by lower-hybrid-(LH-) driven current, the plasma current and its rampup rate increase. Here, EC-driven current is generated by EC heating of the mildly relativistic electrons in LH-driven plasma.

SUMMARYAnti-neutrophil cytoplasmic antibodies (ANCA) in sera from ulcerative colitis (UC) patients have been described as reacting with proteins in the granules of human neutrophils such as cathepsin G and lactoferrin and with yet unidentified antigens. Here we report the existence of a new member of perinuclear ANCA (P-ANCA) in UC patients. In the previous study, we found that UC patients had a novel P-ANCA against neutrophil 28-kD protein. In this study, we purified the same antigens from HL-60 lysates by using reversed phase high-performance liquid chromatography, and revealed that the 28-kD antigen consisted of two different proteins. The N-terminus amino acids of these proteins are identical with those of high mobility group (HMG) non-histone chromosomal proteins HMG1 and HMG2. Immunoblotting analysis of human neutrophil lysates using rabbit anti-HMG1/2 antisera revealed a single band of 28 kD, and the 28-kD band detected by immunoblotting analysis using patient's serum IgG completely disappeared after preincubation with a mixture of HMG1 and HMG2. Furthermore, rabbit anti-HMG1/2 antisera showed a perinuclear staining pattern in indirect immunofluorescence studies using ethanol-fixed neutrophils. These data demonstrate that HMG1 and HMG2 are novel target antigens of P-ANCA. HMG1 and HMG2 are distributed in the nuclei and cytoplasm of eukaryotic cells and act as transcription factors. Their intracellular localization and functions are distinct from those of the previously reported granular antigens of P-ANCA.

No abstract

Ion transport from one aqueous (W1) to another (W2) across bilayer lipid membranes (BLM) containing gramicidin A (GA) was investigated by recording current fluctuations, when various alkali metal chlorides and potassium salts were used as supporting electrolytes. The magnitude of the single-channel current at a given membrane potential depended on not only the cationic species, but also on the anionic species, and then it decreased with an increase in the diameter of the anion when the diameter of the anion was larger than the pore size of the GA channel. The baseline of the recording current, however, increased with an increase in the diameter of the anion, and its height depended on the concentration of GA in the BLM. The results indicate that GA serves as not only a channel-forming compound, but also as a carrier compound in the BLM.

The present study demonstrated that species-specific ecdysone-agonist-based insecticides can be developed, but their species specificity is not based on differences in the activation of the ecdysone receptor but rather on unidentified in vivo parameters such as permeability of the cuticle, uptake/excretion by the gut or metabolic detoxification.